Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2023-12-28 00:00:00 ET · period of report 2023-12-26 · accession 0001209191-23-059885 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-12-28 | 2023-12-26 | BBIO | MCCORMICK FRANK | Dir | S - Sale | $42.06 | -100.0K | 627.7K | -14% | -$4.21M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-26 | S | D | 100,000 | $42.06 | 627,689 | I See Footnote | — | — | (F2) Represents the weighted average sale price of the shares sold from $42.00 to $42.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. (F3) By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017. |